Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza seasonal trivalent
- Development stage
- Approved
- Lead developer
- Vaxart
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Influenza seasonal trivalent is an oral tablet vaccine candidate currently in preclinical development by Vaxart (Agora Merger Sub) for the prevention of seasonal influenza. The vaccine is based on Vaxart's proprietary non-replicating Adenovirus Type 5 (Ad5) viral vector platform and incorporates a double-stranded RNA (dsRNA) adjuvant, which acts as a Toll-like receptor 3 (TLR3) agonist to enhance mucosal and systemic immunity. As a trivalent formulation, it is designed to target three influenza strains in accordance with World Health Organization (WHO) recommendations: two Influenza A lineages (H1N1 and H3N2) and one Influenza B lineage (Victoria). The delivery system is unique in that it is formulated as an oral tablet, intended to be administered as one tablet per strain, providing a room-temperature stable alternative to traditional injectable vaccines.
- Other names
- Influenza Seasonal (Trivalent)Vaxart trivalent influenza vaccine
02
Targets
HA (Hemagglutinin)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on influenza seasonal trivalent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza seasonal trivalent.